Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction
Open accessThe DOI matches its Crossref record; 84 of the 89 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in underlying mechanisms for memory formation such as hippocampal long-term potentiation. Our aim was to identify small molecules with stimulatory effects on the signaling of two neurotrophins, the nerve growth factor (NGF) and the brain derived neurotrophic factor (BDNF). To identify molecules that could potentiate neurotrophin signaling, 25,000 molecules were screened, which led to the identification of the triazinetrione derivatives ACD855 (Ponazuril) and later on ACD856, as positive allosteric modulators of tropomyosin related kinase (Trk) receptors. ACD855 or ACD856 potentiated the cellular signaling of the neurotrophin receptors with EC50 values of 1.9 and 3.2 or 0.38 and 0.30 µM, respectively, for TrkA or TrkB. ACD855 increased acetylcholine levels in the hippocampus by 40% and facilitated long term potentiation in rat brain slices. The compounds acted as cognitive enhancers in a TrkB-dependent manner in several different behavioral models. Finally, the age-induced cognitive dysfunction in 18-month-old mice could be restored to the same level as found in 2-month-old mice after a single treatment of ACD856. We have identified a novel mechanism to modulate the activity of the Trk-receptors. The identification of the positive allosteric modulators of the Trk-receptors might have implications for the treatment of Alzheimer’s diseases and other diseases characterized by cognitive impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a phase I study (NCT05077501), the novel Trk receptor PAM ACD856 (58).557 demonstrated good safety and tolerability, as well as favorable pharmacokinetic properties, potentially benefiting neurotrophic factor signaling.558”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [557]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Preclinical studies identify TrkB positive allosteric modulators as stabilizers of induced plasticity, converting transient synaptic change into a more durable circuit state [114,115].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [114]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“The observed decreased secretion of BDNF in cultured hippocampal neurons transfected with the met allele suggests that reduced BDNF levels might cause decreased cognitive function [14].”
BackgroundNeurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Purification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822 · cited 1×
“The neurotrophins, including the nerve growth factor (NGF) [1], brainderived neurotrophic factor (BDNF) [2], and neurotrophin (NT)-3 [3,4] and NT-4/5 [5], binds the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB and TrkC) [6].”
BackgroundNeurotrophin-3: a Neurotrophic Factor Related to NGF and BDNF
Maisonpierre, P. C., Belluscio, L., Squinto, S., Ip, N. Y., Furth, M. E., Lindsay, R. M., & Yancopoulos, G. D. (1990) · Science · doi:10.1126/science.2321006 · Cited by 1,322 · cited 1×
“The neurotrophins, including the nerve growth factor (NGF) [1], brainderived neurotrophic factor (BDNF) [2], and neurotrophin (NT)-3 [3,4] and NT-4/5 [5], binds the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB and TrkC) [6].”
BackgroundFigurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., & Lu, B. (1996) · Nature · doi:10.1038/381706a0 · Cited by 1,106
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“The transplantation of stem cells or the lentiviral delivery of BDNF into the brains of amyloid transgenic mice or primates have shown the reversal of synapse loss and improved cognition [11].”
BackgroundNeurotrophin-5: A novel neurotrophic factor that activates trk and trkB
Berkemeier, L. R., Winslow, J. W., Kaplan, D. R., Nikolics, K., Goeddel, D. V., & Rosenthal, A. (1991) · Neuron · doi:10.1016/0896-6273(91)90287-a · Cited by 836 · cited 1×
“The neurotrophins, including the nerve growth factor (NGF) [1], brainderived neurotrophic factor (BDNF) [2], and neurotrophin (NT)-3 [3,4] and NT-4/5 [5], binds the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB and TrkC) [6].”
BackgroundEssential Role for TrkB Receptors in Hippocampus-Mediated Learning
Minichiello, L., Korte, M., Wolfer, D., Kühn, R., Unsicker, K., Cestari, V., Rossi-Arnaud, C., Lipp, H.-P., Bonhoeffer, T., & Klein, R. (1999) · Neuron · doi:10.1016/s0896-6273(00)80853-3 · Cited by 799 · cited 1×
“However, the animals displayed impaired learning in more complex or stressful models such as water maze [85], suggesting that some complex tasks are dependent on BDNF/TrkB-signaling in the hippocampus to a larger extent than less complex tasks.”
BackgroundErnfors, P., Ibáñez, C. F., Ebendal, T., Olson, L., & Persson, H. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.14.5454 · Cited by 700 · cited 1×
“The neurotrophins, including the nerve growth factor (NGF) [1], brainderived neurotrophic factor (BDNF) [2], and neurotrophin (NT)-3 [3,4] and NT-4/5 [5], binds the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB and TrkC) [6].”
BackgroundA selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone
Jang, S.-W., Liu, X., Yepes, M., Shepherd, K. R., Miller, G. W., Liu, Y., Wilson, W. D., Xiao, G., Blanchi, B., Sun, Y. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913572107 · Cited by 686 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundAntidepressant drugs act by directly binding to TRKB neurotrophin receptors
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.034 · Cited by 663
Novel Object Recognition Test for the Investigation of Learning and Memory in Mice
Lueptow, L. M. (2017) · Journal of Visualized Experiments · doi:10.3791/55718-v · Cited by 509 · cited 1×
“The experiment was performed as described by Lueptow [58].”
MethodLearning deficit in BDNF mutant mice.
Linnarsson, S., Björklund, A., & Ernfors, P. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01687.x · Cited by 471 · cited 1×
“Finally, it was demonstrated early on that BDNF plays an important role in the formation of spatial memory since BDNF knockout animals display severe memory impairment using the Morris water maze [88].”
MethodThe Cholinergic Lesion of Alzheimer's Disease: Pivotal Factor or Side Show?
Mesulam, M. (2004) · Learning & Memory · doi:10.1101/lm.69204 · Cited by 467 · cited 1×
“Degeneration of the BF cholinergic neurons (BFCN) is one of the earliest signs of cognitive decline and precedes AD development [19,20].”
BackgroundRegulation of hippocampal synaptic plasticity by BDNF
Leal, G., Afonso, P. M., Salazar, I. L., & Duarte, C. B. (2015) · Brain Research · doi:10.1016/j.brainres.2014.10.019 · Cited by 410 · cited 1×
“, long-term potentiation [7], a cellular mechanism proposed”
BackgroundSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundAcute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons
Ji, Y., Lu, Y., Yang, F., Shen, W., Tang, T. T.-T., Feng, L., Duan, S., & Lu, B. (2010) · Nature Neuroscience · doi:10.1038/nn.2505 · Cited by 340
Alonso, M., Vianna, M. R. M., Depino, A. M., Mello e Souza, T., Pereira, P., Szapiro, G., Viola, H., Pitossi, F., Izquierdo, I., & Medina, J. H. (2002) · Hippocampus · doi:10.1002/hipo.10035 · Cited by 339 · cited 2×
“For instance, one study demonstrated a rapid and transient increase in BDNF mRNA in the CA1 region of the dorsal hippocampus after inhibitory avoidance training but failed to show increased levels of BDNF protein [86].”
BackgroundProtective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats
Arancibia, S., Silhol, M., Moulière, F., Meffre, J., Höllinger, I., Maurice, T., & Tapia-Arancibia, L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.05.012 · Cited by 317
EFFECTS OF MOUSE TUMOR TRANSPLANTATION ON THE NERVOUS SYSTEM
Levi‐Montalcini, R. (1952) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1952.tb26548.x · Cited by 269 · cited 1×
“The neurotrophins, including the nerve growth factor (NGF) [1], brainderived neurotrophic factor (BDNF) [2], and neurotrophin (NT)-3 [3,4] and NT-4/5 [5], binds the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB and TrkC) [6].”
BackgroundJiao, S.-S., Shen, L.-L., Zhu, C., Bu, X.-L., Liu, Y.-H., Liu, C.-H., Yao, X.-Q., Zhang, L.-L., Zhou, H.-D., Walker, D. G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.186 · Cited by 266
Nordström, P., Religa, D., Wimo, A., Winblad, B., & Eriksdotter, M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht182 · Cited by 184 · cited 1×
“Additional studies have shown that treatment using AChEIs is associated with reduced mortality in AD patients [75,76], a reduced risk for stroke [76], and a 37% reduction of cardiovascular events in persons with dementia treated with AChEIs [77].”
BackgroundSelf-citationReduction of cortical TrkA but not p75NTR protein in early‐stage Alzheimer's disease
Counts, S. E., Nadeem, M., Wuu, J., Ginsberg, S. D., Saragovi, H. U., & Mufson, E. J. (2004) · Annals of Neurology · doi:10.1002/ana.20233 · Cited by 183 · cited 1×
“A decreased ratio of TrkA/p75 was found in AD [80], which therefore may lead to increased apoptotic signaling induced by pro-NGF.”
BackgroundLong-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182 · cited 2×
“A recent study where 11,652 Alzheimer’s dementia patients using AChEIs were compared to 5826 non-AChEI users in a 5-year follow up, demonstrated that the AChEIs-users had higher MMSE and a lower mortality rate than non-users [74].”
BackgroundResultSelf-citationInnovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Mitra, S., Behbahani, H., & Eriksdotter, M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00038 · Cited by 159
Self-citationJang, S.-W., Okada, M., Sayeed, I., Xiao, G., Stein, D., Jin, P., & Ye, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706662104 · Cited by 158 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundEriksdotter-Jönhagen, M., Linderoth, B., Lind, G., Aladellie, L., Almkvist, O., Andreasen, N., Blennow, K., Bogdanovic, N., Jelic, V., Kadir, A., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000336051 · Cited by 158
Self-citationJang, S.-W., Liu, X., Chan, C.-B., Weinshenker, D., Hall, R. A., Xiao, G., & Ye, K. (2009) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.05.010 · Cited by 144 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundEyjolfsdottir, H., Eriksdotter, M., Linderoth, B., Lind, G., Juliusson, B., Kusk, P., Almkvist, O., Andreasen, N., Blennow, K., Ferreira, D., et al. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0195-9 · Cited by 137
Self-citationBDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124 · cited 1×
“These changes were not found in healthy adult Met carriers with a low amyloid burden [18].”
BackgroundA New Nerve Growth Factor-Mimetic Peptide Active on Neuropathic Pain in Rats
Colangelo, A. M., Bianco, M. R., Vitagliano, L., Cavaliere, C., Cirillo, G., De Gioia, L., Diana, D., Colombo, D., Redaelli, C., Zaccaro, L., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5201-07.2008 · Cited by 116
Madjid, N., Elvander-Tottie, E., Lüttgen, M., Meister, B., Sandin, J., Kuzmin, A., Stiedl, O., & Ögren, S. O. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.092262 · Cited by 113 · cited 1×
“The passive avoidance (PA) task is an associate learning paradigm that is based on Pavlovian fear-conditioning and instrumental conditioning and conducted as previously described [57] in male C57BL/6J mice (n = 7–8/group) from Charles River Laboratories, Sulzfeld, Germany.”
MethodSelf-citationSmall Peptide Mimics of Nerve Growth Factor Bind TrkA Receptors and Affect Biological Responses
LeSauteur, L., Wei, L., Gibbs, B. F., & Saragovi, H. U. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6564 · Cited by 111
A Designed Peptidomimetic Agonistic Ligand of TrkA Nerve Growth Factor Receptors
Maliartchouk, S., Feng, Y., Ivanisevic, L., Debeir, T., Cuello, A. C., Burgess, K., & Saragovi, H. U. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23211-9 · Cited by 105
Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice
Kemppainen, S., Rantamäki, T., Jerónimo-Santos, A., Lavasseur, G., Autio, H., Karpova, N. N., Kärkkäinen, E., Stavén, S., Miranda, H. V., Outeiro, T. F., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.006 · Cited by 100
Gooney, M., Shaw, K., Kelly, Á., O'Mara, S. M., & Lynch, M. A. (2002) · Behavioral Neuroscience · doi:10.1037//0735-7044.116.3.455 · Cited by 94
Franzmeier, N., Ren, J., Damm, A., Monté-Rubio, G., Boada, M., Ruiz, A., Ramirez, A., Jessen, F., Düzel, E., Rodríguez Gómez, O., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0404-6 · Cited by 89
Işık, A. T., Soysal, P., Stubbs, B., Solmi, M., Basso, C., Maggi, S., Schofield, P., Veronese, N., & Mueller, C. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15415 · Cited by 88 · cited 5×
“Currently, marketed AD therapeutics are limited to two different categories of symptomatic therapies: acetylcholinesterase inhibitors (AChEIs) and the NMDA antagonist memantines.”
BackgroundInfluentialXie, Y., Tisi, M. A., Yeo, T. T., & Longo, F. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005071200 · Cited by 84
Kritzner, S., Sager, H., Blum, J. W., Krebber, R., Greif, G., & Gottstein, B. (2002) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-1-4 · Cited by 81
Tiveron, C., Fasulo, L., Capsoni, S., Malerba, F., Marinelli, S., Paoletti, F., Piccinin, S., Scardigli, R., Amato, G., Brandi, R., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.22 · Cited by 80 · cited 1×
“These alterations have also been observed in AD-like mice models [81].”
BackgroundYoshitake, T., Yoshitake, S., Fujino, K., Nohta, H., Yamaguchi, M., & Kehr, J. (2004) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2004.04.041 · Cited by 80 · cited 1×
“The microdialysis experiments were conducted using Pronexus AB, Bromma, Sweden (ethical permit N24/14) on awake, freely moving Sprague Dawley rats (n = 6, 7–8 weeks old from Janvier Labs, Le Genest-Saint-Isle, France) as previously described [52,53].”
MethodLim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., Maruff, P., Snyder, P. J., Masters, C. L., Allegri, R., et al. (2016) · Brain · doi:10.1093/brain/aww200 · Cited by 76 · cited 1×
“In line with these data, it has also been found that BDNF Val66Met polymorphism leads to impaired memory performance, decreased hippocampal glucose metabolism and increased Tau protein and phosphorylated Tau in CSF from patients with preclinical familiar AD [13].”
BackgroundPhase II clinical trials of anti–amyloid β antibodies: When is enough, enough?
Gold, M. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.04.005 · Cited by 75 · cited 2×
“Although the results from the next generation of anti-amyloid treatments are eagerly awaited, many of the clinical trials using substances targeting the amyloidogenic pathway have hitherto failed [79], and there is an urgent need to develop novel therapeutics targeting other, non-Aβ targets.”
BackgroundToltrazuril effective against a broad spectrum of protozoan parasites
Mehlhorn, H., Schmahl, G., & Haberkorn, A. (1988) · Parasitology Research · doi:10.1007/bf00931192 · Cited by 74
Ikegaya, Y., Ishizaka, Y., & Matsuki, N. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02051.x · Cited by 74
Triaca, V., Sposato, V., Bolasco, G., Ciotti, M. T., Pelicci, P., Bruni, A. C., Cupidi, C., Maletta, R., Feligioni, M., Nisticò, R., et al. (2016) · Aging Cell · doi:10.1111/acel.12473 · Cited by 73
BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention
Boots, E. A., Schultz, S. A., Clark, L. R., Racine, A. M., Darst, B. F., Koscik, R. L., Carlsson, C. M., Gallagher, C. L., Hogan, K. J., Bendlin, B. B., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003980 · Cited by 70 · cited 1×
“Moreover, human carriers of the BDNF Val66Met polymorphism, which ultimately results in decreased levels of secreted BDNF, have shown increased rates of decline in memory and hippocampal atrophy relative to Val66Val carriers in the preclinical and prodromal stages of sporadic AD [12].”
BackgroundLow molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity
Scarpi, D., Cirelli, D., Matrone, C., Castronovo, G., Rosini, P., Occhiato, E. G., Romano, F., Bartali, L., Clemente, A. M., Bottegoni, G., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.80 · Cited by 67 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundCapsoni, S., Brandi, R., Arisi, I., D’Onofrio, M., & Cattaneo, A. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711796235032 · Cited by 65 · cited 1×
“Moreover, in the AD11 mice model, which expresses anti-NGF antibodies specifically in the brain, the lack of mature NGF leads to early inflammation and neurodegeneration that is characteristic to Alzheimer’s disease [82].”
BackgroundKarami, A., Eyjolfsdottir, H., Vijayaraghavan, S., Lind, G., Almqvist, P., Kadir, A., Linderoth, B., Andreasen, N., Blennow, K., Wall, A., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.008 · Cited by 63
Self-citationAPOE and BDNF Val66Met polymorphisms combine to influence episodic memory function in older adults
Ward, D. D., Summers, M. J., Saunders, N. L., Janssen, P., Stuart, K. E., & Vickers, J. C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.022 · Cited by 60
Efficacy of ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis.
Furr, M., Kennedy, T., MacKay, R. J., Reed, S., Andrews, F. M., Bernard, B., Bain, F. T., & Byars, D. (2001) · PubMed · Cited by 58
Female-specific effect of the BDNF gene on Alzheimer's disease
Li, G.-D., Bi, R., Zhang, D., Xu, M., Luo, R., Wang, D., Fang, Y., Li, T., Zhang, C., & Yao, Y. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.023 · Cited by 58
Гудашева, Т. А., Povarnina, P. Y., Антипова, Т. А., Firsova, Y. N., Konstantinopolsky, M. A., & Середенин, С. Б. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0198-z · Cited by 57
Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia
Tan, E. C. K., Johnell, K., Ptacek, S. G., Haaksma, M. L., Fastbom, J., Bell, J. S., & Eriksdotter, M. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.02.011 · Cited by 57 · cited 1×
“Additional studies have shown that treatment using AChEIs is associated with reduced mortality in AD patients [75,76], a reduced risk for stroke [76], and a 37% reduction of cardiovascular events in persons with dementia treated with AChEIs [77].”
BackgroundSelf-citationGudasheva, T. A., Povarnina, P., Logvinov, I. O., Antipova, T. A., & Seredenin, S. B. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s118768 · Cited by 55
Jeon, S. J., Lee, H. J., Lee, H. E., Park, S. J., Gwon, Y., Kim, H., Zhang, J., Shin, C. Y., Kim, D. H., & Ryu, J. H. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.029 · Cited by 50
The non‐peptidyl fungal metabolite L‐783,281 activates TRK neurotrophin receptors
Wilkie, N., Wingrove, P. B., Bilsland, J. G., Young, L., Harper, S. J., Hefti, F., Ellis, S., & Pollack, S. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00504.x · Cited by 49 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundJain, P., Li, R., Lama, T., Saragovi, H. U., Cumberlidge, G., & Meerovitch, K. (2011) · Experimental Eye Research · doi:10.1016/j.exer.2011.06.014 · Cited by 47
Kehr, J., Dechent, P., Kato, T., & Ögren, S. O. (1998) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(98)00074-0 · Cited by 46 · cited 1×
“The microdialysis experiments were conducted using Pronexus AB, Bromma, Sweden (ethical permit N24/14) on awake, freely moving Sprague Dawley rats (n = 6, 7–8 weeks old from Janvier Labs, Le Genest-Saint-Isle, France) as previously described [52,53].”
MethodPediaditakis, I., Efstathopoulos, P., Prousis, K. C., Zervoú, M., Arévalo, J. C., Alexaki, V. I., Nikoletopoulou, V., Karagianni, E., Potamitis, C., Tavernarakis, N., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.007 · Cited by 46
Francis, P. T., Parsons, C. G., & Jones, R. W. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.124 · Cited by 45 · cited 1×
“It has been suggested that an approach combining cholinergic with glutamatergic treatment could be a beneficial symptomatic treatment for Alzheimer’s disease [84].”
BackgroundDaumas, S., Sandin, J., Chen, K. S., Kobayashi, D., Tulloch, J., Martin, S. J., Games, D., & Morris, R. G. M. (2008) · Learning & Memory · doi:10.1101/lm.990208 · Cited by 40 · cited 1×
“Male C57BL/6J mice (n = 8/group) from Taconic, Lille Skensved, Denmark, 7–8 weeks of age at arrival, were used in experiments that were predominantly performed as described previously [56].”
MethodSelf-citationTriaca, V., & Calissano, P. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.193224 · Cited by 40
Detection, quantifications and pharmacokinetics of toltrazuril sulfone (Ponazuril®) in cattle
Dirikolu, L., YOHN, R., Garrett, E. F., Chakkath, T., & Ferguson, D. C. (2008) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2008.01039.x · Cited by 39 · cited 2×
“Ponazuril was chosen as the lead candidate for repurposing [64] based upon its pharmacokinetic properties [65], the lack of further oxidation on the sulfur-linker, convincing existing safety pharmacology and toxicology data [66], a promising pharmacological modulation of TrkA and TrkB-signaling, and it was renamed to…”
BackgroundGrundman, M., Capparelli, E. V., Kim, H. T., Morris, J. C., Farlow, M. R., Rubin, E. H., Heidebrink, J. L., Hake, A., Ho, G. J., Schultz, A. N., et al. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00320-5 · Cited by 37 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundPattarawarapan, M., Zaccaro, M. C., Saragovi, U. H., & Burgess, K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0255421 · Cited by 36
Neuroprotection by Small Molecule Activators of the Nerve Growth Factor Receptor
Lin, B., Pirrung, M. C., Deng, L., Li, Z., Liu, Y., & Webster, N. J. G. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.118034 · Cited by 29 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundIto, M., Tsuchida, Y., Mizoue, K., & Hanada, K. (1992) · The Journal of Antibiotics · doi:10.7164/antibiotics.45.1566 · Cited by 27 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundAssociation of TrkA and APP Is Promoted by NGF and Reduced by Cell Death-Promoting Agents
Canu, N., Pagano, I., La Rosa, L. R., Pellegrino, M., Ciotti, M. T., Mercanti, D., Moretti, F., Sposato, V., Triaca, V., Petrella, C., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00015 · Cited by 24
Ito, M., SAKAI, N., Ito, K., Mizobe, F., Hanada, K., Mizoue, K., Bhandari, R., Eguchi, T., & Kakinuma, S. (1999) · The Journal of Antibiotics · doi:10.7164/antibiotics.52.224 · Cited by 23 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundControl of an outbreak of mouse coccidiosis in a closed colony
Haberkorn, A., Friis, C., Schulz, H. P., Meister, G., & Feller, W. (1983) · Laboratory Animals · doi:10.1258/002367783781070803 · Cited by 23
Efficacy of toltrazuril in the prevention of coccidiosis in naturally infected lambs on pasture
Gjerde, B., & Helle, O. (1986) · Acta veterinaria Scandinavica · doi:10.1186/bf03548565 · Cited by 23
Kehr, J., Hu, X.-J., Yoshitake, T., & Scheller, D. (2006) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.066 · Cited by 21
Turnbull, M. T., Boskovic, Z., & Coulson, E. J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00051 · Cited by 21 · cited 1×
“Degeneration of the BF cholinergic neurons (BFCN) is one of the earliest signs of cognitive decline and precedes AD development [19,20].”
BackgroundDetection, quantifications, and pharmacokinetics of ponazuril in healthy swine
Zou, M., Guo, G., Zhao, Y., & Zhang, Q. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12126 · Cited by 16 · cited 1×
“The fact that ACD855 (Ponazuril) has been used as a safe and well tolerated veterinary medicine for long time [62,83] has made it a suitable candidate for repurposing in humans as a cognitive enhancer.”
BackgroundSafety of ponazuril 15% oral paste in horses.
Kennedy, T. J., Campbell, J., & Selzer, V. (2001) · PubMed · Cited by 15
Blanco-Silvente, L., Cervelló, X. C., Garre‐Olmo, J., Franch, J. V., Sáez, M., Barceló, M. A., & Capellà, D. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02742-w · Cited by 13 · cited 1×
“On the other hand, a meta-analysis of randomized controlled trials with a mean duration of 30 weeks and a few randomized controlled trials (RCTs) lasting longer (mean 8 months) showed no significant effect of AChEI on cognition [78].”
BackgroundForsell, P. K. A. L., Almqvist, H., Hillertz, P., Åkerud, T., Otrocka, M., Eisele, L., Sun, K., Andersson, H., Trivedi, S., Wollberg, A. R., et al. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113479401 · Cited by 10 · cited 1×
“The assay was performed as previously described [51].”
MethodSelf-citationHolmes, M., Maysinger, D., Foerster, A. P., Pertens, E., Barlas, C., & Diamond, J. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/s1044-7431(03)00217-3 · Cited by 7 · cited 1×
“Several attempts to identify and develop small molecule activators of neurotrophin signaling have been made, including peptidometics [28–35], small molecules with agonistic properties such as 7,8-dihydroxyflavone [36], gambogic amide [37], amitriptyline [38], LM22A [39] AIT-082 [40,41], L-783,281 and its analogues [42…”
BackgroundDahlström, M., Nordvall, G., Sundström, E., Åkesson, E., Tegerstedt, G., Eriksdotter, M., & Forsell, P. K. A. L. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14513 · Cited by 7 · cited 2×
“For instance, a double mutant of NGF, NGF-K95A/Q96A, could activate the TrkA receptor to a higher degree than NGF itself [55].”
BackgroundMethodSelf-citationStimulating Neurotrophin Receptors in the Treatment of Neurodegenerative Disorders
Nordvall, G., & Forsell, P. K. A. L. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00005-5 · Cited by 3
Self-citation
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Róg, T., Girych, M., & Bunker, A. (2021) · Pharmaceuticals · doi:10.3390/ph14101062 · Cited by 70
Zhou, Z., Liu, C., Xu, S., Wang, J., Guo, F., Duan, S., Deng, Q., Sun, J., Fu, Y., Zhou, Y., et al. (2022) · Basic Research in Cardiology · doi:10.1007/s00395-022-00939-2 · Cited by 53
“They are also involved in the mechanisms underlying memory formation, such as long-term potentiation (LTP) [6].”
BackgroundNeurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Self-citationParrado‐Fernández, C., Juric, S., Backlund, M., Dahlström, M., Madjid, N., Lidell, V., Rasti, A., Sandin, J., Nordvall, G., & Forsell, P. K. A. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241311159 · Cited by 21
“9 ng/mL, which is in line with previously reported EC50-values for BDNF binding to TrkB [37].”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Dahlström, M., Madjid, N., Nordvall, G., Halldin, M. M., Vazquez-Juarez, E., Lindskog, M., Sandin, J., Winblad, B., Eriksdotter, M., & Forsell, P.
- Affiliations
- Karolinska Institutet (SE)
- AlzeCure Pharma (Sweden) (SE)
- Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 171 77 Solna, Sweden
- Karolinska University Hospital (SE)
- Corresponding author
- Forsell, Pontus
- ORCID
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2021-07-23
- Volume
- 10
- Issue
- 8
- Pages
- 1871
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC8391421
- OpenAlex
- W3184010507
- Cited by
- 33
- References
- 89
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 4
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Alzheimer's Drug Discovery Foundation (20151003)
- VINNOVA (2014-00347)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- positive allosteric modulators, neurotrophin receptors, Trk receptors, TrkB, TrkA, nerve growth factor, brain-derived neurotrophic factor, Alzheimer's disease, cognitive impairment, nootropic drugs, long-term potentiation, acetylcholine, small molecule screening
- MeSH terms
- Age Factors, Animals, Behavior, Animal, Brain, Cognition, Disease Models, Animal, Humans, Male, Membrane Glycoproteins, Mice, Inbred C57BL, Motor Activity, Protein-Tyrosine Kinases, Triazines, Signal Transduction, Rats, Sprague-Dawley, Receptors, Nerve Growth Factor, Nootropic Agents, Maze Learning, Receptor, trkB, Receptor, trkA, Cell Line, Tumor, Mice, Rats, Small Molecule Libraries, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.